News

Corcept Therapeutics has received notice that it will be issued a new patent in the U.S. covering the use of Korlym (mifepristone), in combination with strong CYP3A inhibitors, to treat patients with Cushing’s syndrome. Upon issuance from the U.S. Patent and Trademark Office, the company plans to add…

A man with Cushing’s disease — caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma — who later developed metastases in the central nervous system without Cushing’s recurrence, was successfully treated over eight years with radiation and chemotherapy, according to a case report. The report, “Long-term survival…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Patients with Cushing’s syndrome showed less abdominal fat and increased muscle mass, as well as reduced use of medications one year after having their adrenal glands removed, according to a new study. The research, “Changes of computed tomography-based body composition after adrenalectomy in patients with endogenous hypercortisolism,” was…

Ultrasound scans can be useful to monitor muscle changes in patients with glucocorticoid-induced muscle disease or steroid myopathy, and could become an effective routine procedure for those with Cushing’s disease, a study reports. The study, “Ultrasound‑based detection of glucocorticoid‑induced impairments of muscle mass and structure in Cushing’s disease,” was published…

Recognizing discrepancies between blood tests of adenocorticotropic hormone (ACTH) levels and patients’ clinical data is important for clinicians to avoid unnecessary testing or misdiagnosis, a case series highlights. The study, “Corticotropin hormone assay interference: A case series,” was published in the journal Clinical Biochemistry. Cushing’s syndrome comprises…

A first patient has been dosed in a Phase 3 trial testing relacorilant as a possible treatment for Cushing’s syndrome, the investigative treatment’s maker, Corcept Therapeutics, announced a press release. The trial, called GRACE (NCT03697109), is enrolling up to 130 endogenous Cushing’s patients at clinical sites in the U.S., Canada and Europe.

Competent physicians and long-term medical care are the types of support that most help patients with Cushing’s syndrome cope with their condition, a patient-reported survey in the U.S. and Germany shows. U.S. and German patients, however, had different interests regarding other supportive…

Higher levels of sex corticosteroid hormones — such as testosterone — and an enzyme called lactate dehydrogenase may predict malignancies of adrenal masses in children, according to a study. Findings also revealed that malignant tumors — known as adrenocortical carcinomas (ACCs) — were larger and associated with a worse prognosis than…

Mutations in USP48 and BRAF genes contribute to the overproduction of adrenocorticotropin (ACTH) hormone by the pituitary gland and consequent development of Cushing’s disease, a study shows, linking these genes to the disease for a first time. The study, “Identification…